Skip to content

Disc Medicine IRON Interest coverage

Interest coverage at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
313.8×+310×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-9.3×+1.9×
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-5.6×-2.3×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-7.1×-0.8×

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

Based on trailing twelve months.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's interest coverage?
Disc Medicine (IRON) reported interest coverage of -74.7× in Q1 2026.
How has Disc Medicine's interest coverage changed year-over-year?
Disc Medicine's interest coverage increased by 20.6% year-over-year, from -94.1× to -74.7×.
What is the long-term trend for Disc Medicine's interest coverage?
Over 2 years (2020 to 2025), Disc Medicine's interest coverage has grown at a 309.8% compound annual growth rate (CAGR), from -3.9× to -65.4×.
What does interest coverage mean?
Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.